A Conserved Mechanism of APOBEC3 Relocalization by Herpesviral Ribonucleotide Reductase Large Subunits.


Journal

Journal of virology
ISSN: 1098-5514
Titre abrégé: J Virol
Pays: United States
ID NLM: 0113724

Informations de publication

Date de publication:
01 12 2019
Historique:
received: 09 09 2019
accepted: 17 09 2019
pubmed: 20 9 2019
medline: 17 6 2020
entrez: 20 9 2019
Statut: epublish

Résumé

An integral part of the antiviral innate immune response is the APOBEC3 family of single-stranded DNA cytosine deaminases, which inhibits virus replication through deamination-dependent and -independent activities. Viruses have evolved mechanisms to counteract these enzymes, such as HIV-1 Vif-mediated formation of a ubiquitin ligase to degrade virus-restrictive APOBEC3 enzymes. A new example is Epstein-Barr virus (EBV) ribonucleotide reductase (RNR)-mediated inhibition of cellular APOBEC3B (A3B). The large subunit of the viral RNR, BORF2, causes A3B relocalization from the nucleus to cytoplasmic bodies and thereby protects viral DNA during lytic replication. Here, we use coimmunoprecipitation and immunofluorescence microscopy approaches to ask whether this mechanism is shared with the closely related gammaherpesvirus Kaposi's sarcoma-associated herpesvirus (KSHV) and the more distantly related alphaherpesvirus herpes simplex virus 1 (HSV-1). The large RNR subunit of KSHV, open reading frame 61 (ORF61), coprecipitated multiple APOBEC3s, including A3B and APOBEC3A (A3A). KSHV ORF61 also caused relocalization of these two enzymes to perinuclear bodies (A3B) and to oblong cytoplasmic structures (A3A). The large RNR subunit of HSV-1, ICP6, also coprecipitated A3B and A3A and was sufficient to promote the relocalization of these enzymes from nuclear to cytoplasmic compartments. HSV-1 infection caused similar relocalization phenotypes that required ICP6. However, unlike the infectivity defects previously reported for BORF2-null EBV, ICP6 mutant HSV-1 showed normal growth rates and plaque phenotypes. Combined, these results indicate that both gamma- and alphaherpesviruses use a conserved RNR-dependent mechanism to relocalize A3B and A3A and furthermore suggest that HSV-1 possesses at least one additional mechanism to neutralize these antiviral enzymes.

Identifiants

pubmed: 31534038
pii: JVI.01539-19
doi: 10.1128/JVI.01539-19
pmc: PMC6854502
pii:
doi:

Substances chimiques

Minor Histocompatibility Antigens 0
Proteins 0
Viral Proteins 0
Ribonucleotide Reductases EC 1.17.4.-
Cytosine Deaminase EC 3.5.4.1
APOBEC Deaminases EC 3.5.4.5
APOBEC3 proteins, human EC 3.5.4.5
APOBEC3A protein, human EC 3.5.4.5
APOBEC3B protein, human EC 3.5.4.5
Cytidine Deaminase EC 3.5.4.5

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NCI NIH HHS
ID : F30 CA200432
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI083196
Pays : United States
Organisme : Howard Hughes Medical Institute
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA009138
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA234228
Pays : United States
Organisme : CIHR
ID : 153014
Pays : Canada
Organisme : NCI NIH HHS
ID : F31 CA243306
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM008244
Pays : United States

Informations de copyright

Copyright © 2019 American Society for Microbiology.

Références

Mol Cell Biol. 2018 Nov 13;38(23):
pubmed: 30224517
Nature. 2002 Aug 8;418(6898):646-50
pubmed: 12167863
Semin Cancer Biol. 2014 Jun;26:60-8
pubmed: 24457012
Virology. 1988 Sep;166(1):41-51
pubmed: 2842955
Cell Host Microbe. 2008 Jun 12;3(6):388-98
pubmed: 18541215
Cell. 2003 Jun 13;113(6):803-9
pubmed: 12809610
J Virol. 2010 Aug;84(16):8193-201
pubmed: 20519393
Science. 2004 Mar 19;303(5665):1829
pubmed: 15031497
J Virol. 2008 Sep;82(17):8762-70
pubmed: 18562521
J Biol Chem. 2006 Aug 4;281(31):22161-72
pubmed: 16735504
J Virol. 1975 Aug;16(2):275-83
pubmed: 168402
J Virol. 2003 Feb;77(3):1840-7
pubmed: 12525618
Proc Natl Acad Sci U S A. 2006 Jun 6;103(23):8780-5
pubmed: 16728505
Virus Evol. 2019 Feb 11;5(1):vey040
pubmed: 30792902
J Virol. 1988 Mar;62(3):732-43
pubmed: 2828668
J Biol Chem. 2010 Sep 3;285(36):27664-72
pubmed: 20601642
EMBO J. 2004 Jun 16;23(12):2451-8
pubmed: 15152192
J Immunol. 2003 Jul 15;171(2):886-92
pubmed: 12847258
Sci Adv. 2016 Oct 07;2(10):e1601737
pubmed: 27730215
Nat Microbiol. 2019 Jan;4(1):78-88
pubmed: 30420783
Front Microbiol. 2012 Jan 20;3:6
pubmed: 22319516
Proc Natl Acad Sci U S A. 2005 Jun 7;102(23):8321-6
pubmed: 15919829
J Virol. 1998 Sep;72(9):7563-8
pubmed: 9696854
J Mol Biol. 2018 Aug 17;430(17):2695-2708
pubmed: 29787764
Apoptosis. 2011 Mar;16(3):256-71
pubmed: 21107701
FEMS Microbiol Rev. 2012 May;36(3):684-705
pubmed: 22150699
J Virol. 2006 Nov;80(21):10522-33
pubmed: 16920826
MBio. 2014 Dec 23;5(6):null
pubmed: 25538195
FEBS J. 2009 Dec;276(24):7228-36
pubmed: 19878306
Nature. 2011 Dec 21;481(7381):371-5
pubmed: 22190037
J Virol. 2009 Sep;83(18):9474-85
pubmed: 19587057
J Virol. 1985 Nov;56(2):558-70
pubmed: 2997476
J Biol Chem. 2019 Apr 12;294(15):5759-5773
pubmed: 30755480
PLoS Comput Biol. 2014 Apr 10;10(4):e1003537
pubmed: 24722319
Trends Biochem Sci. 2009 Jan;34(1):25-32
pubmed: 18990579
Blood. 2006 Jul 1;108(1):141-51
pubmed: 16543476
Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3094-9
pubmed: 18287053
J Biol Chem. 2010 Sep 3;285(36):27753-66
pubmed: 20615867
PLoS Pathog. 2009 May;5(5):e1000439
pubmed: 19461882
J Virol. 2016 Jun 24;90(14):6379-6386
pubmed: 27147740
Cell Cycle. 2013 Mar 1;12(5):762-72
pubmed: 23388464
Cell Host Microbe. 2018 May 9;23(5):628-635.e7
pubmed: 29746834
Virology. 2015 May;479-480:160-6
pubmed: 25819165
J Virol. 1997 Oct;71(10):7963-8
pubmed: 9311888
J Gen Virol. 2002 Nov;83(Pt 11):2779-89
pubmed: 12388814
Nat Struct Mol Biol. 2010 Feb;17(2):222-9
pubmed: 20062055
J Virol. 2015 Mar;89(5):2892-905
pubmed: 25540385
Nature. 2013 Feb 21;494(7437):357-60
pubmed: 23407494
J Virol. 2016 Aug 12;90(17):8005-12
pubmed: 27356895
Nature. 2013 Feb 21;494(7437):366-70
pubmed: 23389445
J Virol. 2011 Oct;85(19):9726-36
pubmed: 21775448
Virology. 2015 May;479-480:131-45
pubmed: 25818029
Retrovirology. 2005 May 19;2:32
pubmed: 15943885
Hepatology. 2010 May;51(5):1538-46
pubmed: 20155784
Science. 2008 Apr 11;320(5873):230-3
pubmed: 18403710
Cell Host Microbe. 2015 Feb 11;17(2):229-42
pubmed: 25674982
PLoS Pathog. 2017 Jun 1;13(6):e1006423
pubmed: 28570668
Nat Immunol. 2015 Jun;16(6):546-53
pubmed: 25988886
Nature. 2011 Dec 21;481(7381):376-9
pubmed: 22190036
J Virol. 2001 Dec;75(23):11720-34
pubmed: 11689653
Front Cell Infect Microbiol. 2014 Apr 28;4:52
pubmed: 24809024
J Virol. 1993 Oct;67(10):6125-35
pubmed: 8396674
Proc Natl Acad Sci U S A. 2014 Nov 4;111(44):15786-91
pubmed: 25313075
Nucleic Acids Res. 2004 Mar 19;32(5):1792-7
pubmed: 15034147
Nature. 2005 Jan 27;433(7024):430-3
pubmed: 15674295

Auteurs

Adam Z Cheng (AZ)

Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, Minnesota, USA.
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, USA.
Institute for Molecular Virology, University of Minnesota, Minneapolis, Minnesota, USA.
Center for Genome Engineering, University of Minnesota, Minneapolis, Minnesota, USA.

Sofia N Moraes (SN)

Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, Minnesota, USA.
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, USA.
Institute for Molecular Virology, University of Minnesota, Minneapolis, Minnesota, USA.
Center for Genome Engineering, University of Minnesota, Minneapolis, Minnesota, USA.

Claire Attarian (C)

Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, Minnesota, USA.
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, USA.
Institute for Molecular Virology, University of Minnesota, Minneapolis, Minnesota, USA.
Center for Genome Engineering, University of Minnesota, Minneapolis, Minnesota, USA.

Jaime Yockteng-Melgar (J)

Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.
Facultad de Ciencias de la Vida, Escuela Superior Politécnica del Litoral, Guayaquil, Ecuador.

Matthew C Jarvis (MC)

Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, Minnesota, USA.
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, USA.
Institute for Molecular Virology, University of Minnesota, Minneapolis, Minnesota, USA.
Center for Genome Engineering, University of Minnesota, Minneapolis, Minnesota, USA.

Matteo Biolatti (M)

Laboratory of Pathogenesis of Viral Infections, Department of Public Health and Pediatric Sciences, University of Turin, Turin, Italy.

Ganna Galitska (G)

Laboratory of Pathogenesis of Viral Infections, Department of Public Health and Pediatric Sciences, University of Turin, Turin, Italy.

Valentina Dell'Oste (V)

Laboratory of Pathogenesis of Viral Infections, Department of Public Health and Pediatric Sciences, University of Turin, Turin, Italy.

Lori Frappier (L)

Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.

Craig J Bierle (CJ)

Institute for Molecular Virology, University of Minnesota, Minneapolis, Minnesota, USA.
Department of Pediatrics, Division of Pediatric Infectious Diseases and Immunology, University of Minnesota, Minneapolis, Minnesota, USA.

Stephen A Rice (SA)

Institute for Molecular Virology, University of Minnesota, Minneapolis, Minnesota, USA.
Department of Microbiology and Immunology, University of Minnesota, Minneapolis, Minnesota, USA.

Reuben S Harris (RS)

Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, Minnesota, USA rsh@umn.edu.
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, USA.
Institute for Molecular Virology, University of Minnesota, Minneapolis, Minnesota, USA.
Center for Genome Engineering, University of Minnesota, Minneapolis, Minnesota, USA.
Howard Hughes Medical Institute, University of Minnesota, Minneapolis, Minnesota, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH